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Efﬁcacy and Safety of High Potent P2Y12 Inhibitors Prasugrel and
Ticagrelor in Patients With Coronary Heart Disease Treated With Dual
Antiplatelet Therapy: A Sex-Speciﬁc Systematic Review and
Meta-Analysis
Michelle M. Schreuder, BSc; Ricardo Badal, BSc; Eric Boersma, MSc, PhD; Maryam Kavousi, MD, PhD; Jolien Roos-Hesselink, MD, PhD;
Jorie Versmissen, MD, PhD; Loes E. Visser, MSc, PhD; Jeanine E. Roeters van Lennep, MD, PhD
Background-—Sex differences in efﬁcacy and safety of dual antiplatelet therapy remain uncertain because of the underrepre-
sentation of women in cardiovascular trials. The aim of this study was to perform a sex-speciﬁc analysis of the pooled efﬁcacy and
safety data of clinical trials comparing a high potent P2Y12 inhibitor+aspirin with clopidogrel+aspirin in patients with acute
coronary syndrome.
Methods and Results-—A systematic literature search was performed. Randomized clinical trials that compared patients following
percutaneous coronary intervention/acute coronary syndrome who were taking high potent P2Y12 inhibitors+aspirin versus
clopidogrel+aspirin were selected. Random effects estimates were calculated and relative risks with 95% CIs on efﬁcacy and safety
end points were determined per sex. We included 6 randomized clinical trials comparing prasugrel/ticagrelor versus clopidogrel in
43 990 patients (13 030 women), with a median follow-up time of 1.06 years. Women and men had similar relative risk (RR)
reduction for major cardiovascular events (women: RR, 0.89 [95% CI, 0.80–1.00; men: RR, 0.84 [95% CI, 0.79–0.91) (P for
interaction=0.39). Regarding safety, women and men had similar risk of major bleeding by high-potency dual antiplatelet therapy
(RR, 1.18 [95% CI, 0.98–1.41] versus RR, 1.03 [95% CI, 0.93–1.14]) (P for interaction=0.20).
Conclusions-—The small and statistically insigniﬁcant difference in efﬁcacy and safety estimates of high-potency dual antiplatelet
therapy between women and men following percutaneous coronary intervention/acute coronary syndrome do not justify
differential dual antiplatelet therapy treatment for both sexes. ( J Am Heart Assoc. 2020;9:e014457. DOI: 10.1161/JAHA.119.
014457.)
Key Words: coronary artery disease • dual antiplatelet therapy • sex-speciﬁc
C urrent guidelines for the management of patients withcoronary artery disease (CAD) recommend the use of
dual antiplatelet therapy (DAPT), a combination of aspirin and
an oral inhibitor of the platelet P2Y12 receptor, to reduce
coronary thrombosis and mortality in patients who experi-
enced an acute coronary syndrome (ACS) or who underwent a
percutaneous coronary intervention (PCI). Although DAPT is
effective in decreasing thrombotic complications in these
patients, the therapy increases the risk of bleeding compli-
cations. Therefore, risk assessment balancing thrombotic
versus bleeding risk is warranted before DAPT is considered.1
The next-generation P2Y12 inhibitor prasugrel has a more
rapid onset of action than clopidogrel, attributable to more
efﬁcient metabolic activations,2 and leads to a higher
reduction of ischemic events compared with clopidogrel.3
Later, ticagrelor was developed, which reversibly inhibits the
P2Y12 receptor so the effects can be reversed more easily and
not be a prodrug, leading to a faster onset of action because it
does not require conversion to an active metabolite.4,5 A large
clinical trial also showed higher efﬁcacy of ticagrelor in the
reduction of ischemic events and stent thrombosis (ST)
compared with clopidogrel.6
Therefore, the high potent P2Y12 inhibitors ticagrelor or
prasugrel in combination with aspirin are currently recom-
mended as ﬁrst-choice therapy in patients with ACS.1
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The latest update of the European Society of Cardiology
guidelines on DAPT in patients with CAD state that there is
“no convincing evidence for a gender-related difference in the
efﬁcacy and safety of currently available DAPT type or
duration across studies.”1 However, taking into account that
the typical women to men ratio in these trials is 1:4, analyses
stratiﬁed by sex—if published—are underpowered and
therefore sex differences in efﬁcacy and safety of DAPT
remain uncertain.7 In addition, registries have shown that
women are less likely to be treated with high potent P2Y12
inhibitors than men in clinical practice.8
Currently, it is more recognized that the efﬁcacy and safety
of drugs may differ between men and women. As women have
lower body weight, a higher fat/water balance, and a lower
clearance in general, as well as different hormonal composi-
tion, pharmacokinetics and pharmacodynamics can be
affected.9–11 Therefore, to be able to provide sex- and
gender-speciﬁc guideline recommendations it is important to
verify whether efﬁcacy and safety is equal for speciﬁc drugs,
especially when these are prescribed to a large number of
both male and female patients.
The aim of this study was to perform sex-speciﬁc analyses
of the pooled efﬁcacy and safety data of trials comparing high
potent DAPT prasugrel/ticagrelor against clopidogrel in
patients with ACS with or without PCI.
Methods
Our protocol is published on PROSPERO (ID: CRD420180
82179).
The authors declare that all supporting data are available
within the article (and its online supplementary ﬁles).
Literature Search
We developed a search strategy to identify randomized
controlled trials (RCTs) investigating the efﬁcacy and safety of
aspirin and P2Y12 inhibitors compared with aspirin, aspirin+-
placebo, or clopidogrel+aspirin in patients with CAD. We
performed a systematic literature search in MEDLINE Ovid,
EMBASE, and the Cochrane Central Register of Controlled trials
(latest search performed: June 2018). For the full search
strategies, see Table S1. In addition, reference lists from eligible
trials were reviewed to identify potentially relevant trials.
Population
We considered studies of participants who were assigned to
DAPT for cardiovascular prevention following PCI with or
without coronary stent, or after admission for ACS. Studies
focusing on the use of DAPT in patients undergoing coronary
artery bypass graft surgery were excluded, as the efﬁcacy and
safety of DAPT in these patients is complex and dependent on
pretreatment with PCI.12
Inclusion and Exclusion Criteria
Studies were eligible if they fulﬁlled the following criteria: (1)
original full-text article; (2) RCT or double-blind, single-blind, or
open-label design; (3) DAPT treatment as secondary prevention
after either PCI following documented CAD or a diagnosis of
CAD with a high risk of events, eg, previous myocardial
infarction (MI); (4) DAPT treatment >1 month; (5) analysis on
both cardiovascular outcomes and adverse events; (6) ≥50
participants in the intervention and control group; and (7)
population age ≥18 years. Language was restricted to English.
For our study, the regimen of DAPT was limited to the
following combinations: ticagrelor+aspirin and prasugrel+aspirin
versus clopidogrel+aspirin. Studies analyzing the effect of
cangrelor and elinogrel were excluded as these are administered
intravenously when oral drugs are contraindicated and therefore
the duration of use of these agents is generally limited.
Studieswere excluded if: (1) the population had cardiovascular
disease other than ACS, (2) DAPT was intended as primary
cardiovascular prevention, and (3) the populationwas nonhuman.
If more than 1 published article was available from the same
trial, the article with the most detailed information regarding
cardiovascular outcomes and adverse events was included.
See Table S2 for the full overview of the inclusion and
exclusion criteria.
Data Extraction
A systematic 2-step screening of the literaturewas performed by
2 independent reviewers (R.B. and L.E.V.). The title and abstract
screening was ﬁrst performed, and then the full-text screening.
Clinical Perspective
What Is New?
• Women are less likely to be treated with high potent P2Y12
inhibitors prasugrel/ticagrelor than men in clinical practice.
• Sex-speciﬁc additional risk for cardiovascular end points
and bleeding of prasugrel/ticagrelor compared with clopi-
dogrel is lacking.
What Are the Clinical Implications?
• We showed that there are no signiﬁcant sex differences in
efﬁcacy and safety of the high potent P2Y12 inhibitors
prasugrel/ticagrelor compared with clopidogrel.
• This should lead the way to prescribing guideline-recom-
mended high potent dual antiplatelet therapy in both men
and women.
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Disagreements during the title/abstract and full-text screening
about whether to include a study were resolved by discussion
with a third investigator (M.M.S.) to reach consensus.
Of the included trials, the following relevant data were
extracted: trial name, ﬁrst author, journal, publication year,
country, the blinding method that was applied, treatment of
intervention and control arms, demographic characteristics
(indication, duration of follow-up, sample size), age, and sex.
Efﬁcacy and safety end points were extracted, if reported, for
women and men separately.
If data of the included trials were not available, we
requested both efﬁcacy and safety end points per sex by
contacting the corresponding author.
The risk of bias in the included trials for the meta-analysis
was assessed with the Cochrane Collaboration’s tool13
(Table 1 and Table S3). This tool consists of 6 domains of bias
in which different aspects are covered. The risk per aspect was
categorized by the reviewers as low, unclear, or high.
Efﬁcacy and Safety End Points
The primary efﬁcacy end point was major cardiovascular event
(MACE). For the deﬁnition of MACE per included trial, see
Table S4. The secondary efﬁcacy end points were all-cause
mortality, cardiovascular mortality, MI, stroke, and ST.
The primary safety end point was deﬁned as major
bleeding, based on the thrombolysis in MI bleeding criteria
1; Bleeding Academic Research Consortium (BARC) 2, 3, and
5; or Global Utilization of Streptokinase and TPA for Occluded
Arteries (GUSTO) bleeding criteria 1.14–16 The secondary
safety end point was deﬁned as minor bleeding, based on the
thrombolysis in MI bleeding criteria 2.
Statistical Analyses
Potential sex differences in efﬁcacy and safety of potent P2Y12
inhibitors (prasugrel or ticagrelor)+aspirin versus clopidogrel+
Figure 1. Flowchart describing the screening and selection process. *See Table S3 for the
appropriate exclusion reasons for title and abstract screening.
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aspirin were determined by extracting MACE end points and
major bleeding for women and men separately from the
selected trials. The pooled relative risks (RRs) for efﬁcacy and
safety end points and 95% CIs were then estimated per sex
with a random effect model computed based on the DerSimo-
nian and Laird method.17 Under the null hypothesis, the
difference in ln(RRpooled) between women and men follows
(approximately) a normal distribution. We therefore calculated
the statistic Z difference in ln(RRpooled)/standard error, which
we then compared with the standard normal distribution to
reveal the level of signiﬁcance.
The pooled absolute risk reduction was determined as
follows. First, for each trial, the absolute risks in treatment
and control arms were calculated as the number of
patients with an end point event divided by the corre-
sponding sample size. Then, the absolute risk reduction
was deﬁned as the difference in absolute risk in the
treatment arm minus control. Finally, trial estimates were
pooled using the inverse of the variance of the absolute
risk reductions as weighing factor. Numbers needed to
treat/harm were calculated for the differences in absolute
risk, based on the weighed median duration of follow-up of
all trials.
Statistical analyses were performed in STATA (version 14,
StataCorp LLC) and in R. For the STATA scripts, see Table S5.
All tests were 2-sided, with signiﬁcance deﬁned as a P value
of <0.05.
Heterogeneity
Heterogeneity between studies was assessed based on the
Q-statistic and quantiﬁed by I2 statistic. Moreover, a 95%
prediction interval was determined in order to better report
heterogeneity between studies.18–20 Small-study effects
were assessed using contoured funnel plots and the Egger
test.21
Table 2. Efﬁcacy and Safety Analysis of High Potent P2Y12 Inhibitor+Aspirin vs Clopidogrel+Aspirin
End Points RR (95% CI) Events Intervention Events Control P Value
MACE
High potent P2Y12 inhibitor+aspirin vs clopidogrel+aspirin 0.87 (0.80–0.94) 2211/21 828 2540/21 754 <0.001
Major bleeding
High potent P2Y12 inhibitor+aspirin vs clopidogrel+aspirin 1.06 (0.97–1.17) 901/22 078 842/21 998 0.184
MACE indicates major cardiovascular event; RR, relative risk.
Table 3. Sex-Speciﬁc Efﬁcacy and Safety Analysis of High Potent P2Y12 Inhibitor+Aspirin vs Clopidogrel+Aspirin
Efﬁcacy and Safety Analysis Based on High Potent DAPT vs Clopidogrel+Aspirin
End Points
Female Male
Sex InteractionRR (95% CI) Events Intervention Events Control RR (95% CI) Events Intervention Events Control
MACE* 0.91 (0.83–1.00) 737/6497 818/6543 0.85 (0.80–0.91) 1474/15 410 1722/15 277 P=0.24
All-cause mortality 0.91 (0.79–1.05) 360/6530 396/6574 0.86 (0.77–0.95) 630/15 620 732/15 503 P=0.53
Cardiovascular mortality 0.88 (0.76–1.03) 294/6530 333/6574 0.85 (0.76–0.96) 516/15 620 603/15 503 P=0.72
MI 0.88 (0.78–1.00) 455/6530 520/6574 0.82 (0.74–0.93) 991/15 620 1201/15 503 P=0.41
ST† 0.52 (0.23–1.16) 24/6307 51/6369 0.56 (0.44–0.70) 111/15 416 197/15 286 P=0.86
Stroke‡ 1.03 (0.78–1.37) 100/6497 98/6551 1.02 (0.82–1.26) 178/15 512 174/15 392 P=0.96
Major bleeding 1.18 (0.98–1.41) 237/6509 201/6554 1.03 (0.93–1.14) 664/15 569 641/15 444 P=0.20
Minor bleeding 1.13 (0.75–1.71) 207/6509 196/6554 1.20 (0.94–1.52) 357/15 569 293/15 444 P=0.80
ACS indicates acute coronary syndrome; DAPT, dual antiplatelet therapy; PCI, percutaneous coronary intervention; MI, myocardial infarction; RR, relative risk; NSTEMI, non–ST-segment–
elevation myocardial infarction.
*The TOPIC (Timing of Platelet Inhibition After Acute Coronary Syndrome) trial was not included because they did not report a major cardiovascular event (MACE) end point.
†DISPERSE-2 (Dose Conﬁrmation Study Assessing Anti-Platelet Effects of AZD6140 vs Clopidogrel in NSTEMI 2) was not included because they did not report a stent thrombosis (ST) end
point and the TOPIC ticagrelor and PRASFIT-ACS (Prasugrel Compared With Clopidogrel for Japanese Patients With ACS Undergoing PCI) trials were not included because there were no ST
events during follow-up.
‡TOPIC ticagrelor was not included because there were no stroke events during follow-up. Stroke was deﬁned as either ischemic stroke (TOPIC, TRITON-TIMI 38 [Trial to Assess
Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel–Thrombolysis in Myocardial Infarction 38], and PRASFIT-ACS) or ischemic/hemorrhagic stroke
(DISPERSE-2, TRILOGY ACS [Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes], and PLATO [Platelet Inhibition and Patient
Outcomes] trials).
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Results
Characteristics of the RCTs
Twelve trials were found eligible for inclusion in our meta-
analysis. Five trials reported their outcomes for women and
men separately in the original publications, subanalyses, or in
previously published systematic reviews and meta-analyses
(Figure 1, Table S6). One of the corresponding authors of the
remaining trials who was contacted for their efﬁcacy and
safety outcomes stratiﬁed by sex provided the required sex-
speciﬁc data. Three investigators declined to perform the
additional analyses requested as a result of low capacity in
staff, and 2 authors did not respond to our requests.
Thus, 6 trials with a total of 13 030 (30%) female and
30 960 (70%) male participants were included in our meta-
analysis.
Key characteristics of these trials are presented in
Table 1.3,6,22–25 The weighed median follow-up time was
1.06 years. The population of the PLATO (Platelet Inhibition
and Patient Outcomes), PRASFIT-ACS (Prasugrel Compared
With Clopidogrel for Japanese Patients With ACS Undergoing
PCI), TOPIC (Timing of Platelet Inhibition After Acute Coronary
Syndrome), and TRITON-TIMI 38 (Trial to Assess Improvement
in Therapeutic Outcomes by Optimizing Platelet Inhibition with
Prasugrel–Thrombolysis in Myocardial Infarction 38) trials
consisted of patients with ACS, whereas the DISPERSE-2
(Dose Conﬁrmation Study Assessing Anti-Platelet Effects of
AZD6140 vs Clopidogrel in NSTEMI 2) trial exclusively
enrolled patients with non–ST-segment elevation ACS, and
the TRILOGY ACS (Targeted Platelet Inhibition to Clarify the
Optimal Strategy to Medically Manage Acute Coronary
Syndromes) trial included only patients with non–ST-
segment–elevation myocardial infarction (NSTEMI) or unsta-
ble angina. All trials enrolled patients who underwent
revascularization, except for the TRILOGY ACS trial, in which
patients were only eligible if they received medical treatment
without revascularization after the index event. Prasugrel was
used as the high potent P2Y12 inhibitor in 3 trials, ticagrelor
was used as the high potent P2Y12 inhibitor in 2 trials, and
prasugrel or ticagrelor was used as the high potent P2Y12
inhibitor in 1 trial. In the DISPERSE-2 trial, the 90 mg
ticagrelor dosage group was included as the treatment group.
Quality Assessment
Quality assessment is presented in Table S3. All included
trials scored low on selection bias, performance bias,
detection bias, attrition bias, and reporting bias; therefore,
Figure 2. The relative risk (RR) of major cardiovascular events (MACEs) in women treated with a high potent
P2Y12 inhibitor (prasugrel/ticagrelor) vs clopidogrel. ACS indicates acute coronary syndrome; DISPERSE-2,
Dose Conﬁrmation Study Assessing Anti-Platelet Effects of AZD6140 vs Clopidogrel in NSTEMI 2; PCI,
percutaneous coronary intervention; PLATO, Platelet Inhibition and Patient Outcomes; PRASFIT-ACS, Prasugrel
Compared With Clopidogrel for Japanese Patients With ACS Undergoing PCI; TRILOGY ACS, Targeted Platelet
Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes; NSTEMI, non–ST-
segment–elevation myocardial infarction; TRITON-TIMI 38, Trial to Assess Improvement in Therapeutic
Outcomes by Optimizing Platelet Inhibition with Prasugrel–Thrombolysis in Myocardial Infarction 38.
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all have been evaluated as having low risk of bias. The most
prevalent potential risk of bias was because studies did not
clearly indicate the allocation concealment.
Efﬁcacy Outcomes
High potent P2Y12 inhibitor (prasugrel or ticagrelor)+aspirin
was associated with an additional reduction in MACE compared
with clopidogrel+aspirin (RR, 0.87; 95% CI, 0.80–0.94
[P<0.001]) (Table 2). Women and men had similar relative risk
reduction (women: RR, 0.89 [95% CI, 0.80–1.00]; men: RR, 0.84
[95% CI, 0.79–0.91) (P for interaction=0.39) (Table 3 and
Figures 2 and 33,6,22–25). The number needed to treat with high
potency DAPT versus clopidogrel+aspirin to prevent 1 MACE
was 88 for women and 55 for men based on a weighed median
duration of treatment of 1.06 years (Table 4).
Our secondary efﬁcacy end points (all-cause mortality,
cardiovascular mortality, MI, ST, and stroke) also did not show
any signiﬁcant difference between women andmen (Figures S1
through S10). The statistics of all efﬁcacy end points are
summarized in Table 3. Regarding the absolute numbers,
women compared with men showed less absolute risk reduc-
tion in all-cause mortality (0.3% versus 0.6%), cardiovascular
mortality (0.3 versus 0.4), MI (0.8% versus 1.3%), and ST (1.15%
versus 1.22%) (Table 4). In addition, the absolute risks for the
efﬁcacy end points were slightly higher in women than men for
high potent P2Y12 inhibitors, except for ST and stroke (Table 4).
Safety Outcome
Risk for major bleeding in patients treated with high potent
P2Y12 inhibitor+aspirin compared with clopidogrel+aspirin
was not signiﬁcantly increased (RR, 1.06; 95% CI, 0.97–1.17
[P=0.2]) (Table 2). Also, no differences between women and
men were observed regarding major bleeding in patients
randomized to high potent DAPT versus clopidogrel+aspirin
(women: RR, 1.18 [95% CI, 0.98–1.41]; men: RR, 1.03 [95% CI,
0.93–1.14]) (P for interaction=0.2) (Table 3 and Figures 4 and
53,6,22–25).
Adding prasugrel or ticagrelor to aspirin instead of
clopidogrel was associated with an increased risk of major
bleeding of 0.2% in women and 0.04% in men, resulting in
a number needed to harm for high potent DAPT treat-
ment of 538 women versus 2489 men based on a
weighed median duration of treatment of 1.05 years
(Table 4).
Figure 3. The relative risk (RR) of major cardiovascular events (MACEs) in men treated with a high
potent P2Y12 inhibitor (prasugrel/ticagrelor) vs clopidogrel. ACS indicates acute coronary syndrome;
DISPERSE-2, Dose Conﬁrmation Study Assessing Anti-Platelet Effects of AZD6140 vs Clopidogrel in
NSTEMI 2; NSTEMI, non–ST-segment–elevation myocardial infarction; PCI, percutaneous coronary
intervention; PLATO, Platelet Inhibition and Patient Outcomes; PRASFIT-ACS, Prasugrel Compared With
Clopidogrel for Japanese Patients With ACS Undergoing PCI; TRILOGY ACS, Targeted Platelet Inhibition to
Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes; TRITON-TIMI 38, Trial to
Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel–
Thrombolysis in Myocardial Infarction 38.
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Minor bleeding also showed no sex differences (Table 3
and Figures S11 and S12). Regarding the absolute numbers,
the additional risks for minor bleeding in men using high
potent P2Y12 inhibitor+aspirin were slightly higher compared
with women (0.8% versus 0.3%) (Table 4).
Heterogeneity
Some heterogeneity was found in the efﬁcacy end point of MI
in men between studies for MI in men (I2=29.2%, Q statistic
P=0.205) and ST in women (I2=49.3%, Q statistic P=0.1) with
prediction intervals slightly exceeding the CI of the pooled
effect. However, the Egger test showed no indication for
small-study effects (Figures S13 through S28).
Discussion
Our systematic review and meta-analysis show that the
efﬁcacy and safety of high potent DAPT (prasugrel or
ticragelor in combination with aspirin) compared with clopi-
dogrel+aspirin in patients with ACS are similar in both men
and women. No sex difference was observed in additional
reduction of MACE or increase of bleeding risk in patients
randomized to high potent DAPT versus clopidogrel+aspirin.
However, women randomized to aspirin+clopidogrel had 1.3%
higher MACE risk and 1.1% lower risk of major bleeds, so that
the differences in absolute treatment effects between women
and men were negligibly small. Hence, our study supports
similar DAPT management in both sexes.
Sex Differences in Response to Antiplatelet
Therapy
It has currently been acknowledged that poor response to
clopidogrel can be explained by increased platelet reactiv-
ity.26,27 In vitro studies have shown that women have
increased platelet reactivity compared with men; however,
the underlying mechanism of this sex difference is not
completely understood. It has been suggested that it may be
caused by higher levels of estrogen in women, which leads to
increased platelet to platelet aggregation,28,29 increased
platelet adhesion to ﬁbrinogen,30 and platelet interaction
with leukocytes.31
A subanalysis of the ADAPT-DES (Assessment of Dual
AntiPlatelet Therapy with Drug-Eluting Stents) study (8448
patients [25.6% women who underwent PCI]) compared the
risk for ST and bleeding in patients with high platelet reactivity
(HPR) versus patients without HPR, stratiﬁed by sex. They
found that both men and women with HPR had an increased
risk of ST, but only a signiﬁcantly lower risk of bleeding in
women with HPR was observed.32 They also observed that
HPR was more prevalent in women than men (51.7% versus
39.6%; P<0.0001), which might explain sex differences in
response to treatment with clopidogrel.
However, a sex-speciﬁc meta-analysis of 5 trials includ-
ing 79 613 patients (30% women) compared clopido-
grel+aspirin versus aspirin monotherapy in patients with
CVD and found that DAPT was slightly less effective in the
prevention of CVD in women but there were no signiﬁcant
sex differences in efﬁcacy to prevent MACE or safety
depicted as major bleeding.33 Another meta-analysis
focusing on short- versus long-term DAPT treatment in
men and women, including 6 randomized trials, concluded
that short-term treatment leads to similar rates of MACE as
Table 4. Pooled Absolute Event Rates and NNT/NNH With
High Potent P2Y12 Inhibitor+Aspirin vs Clopidogrel+Aspirin
High Potent
P2Y12
Inhibitor, % Control, %
Absolute
Risk
Difference, % NNT/NNH
MACE
Women 11.1 11.9 0.8 131
Men 9.3 11.1 1.8 58
All-cause mortality
Women 4.8 5.1 0.3 364
Men 3.1 3.7 0.6 191
CVM
Women 4.0 4.3 0.3 424
Men 2.4 2.8 0.4 232
MI
Women 6.9 7.7 0.8 114
Men 6.5 7.8 1.3 74
ST
Women 0.06 1.3 1.2 140
Men 0.6 1 0.4 256
Stroke*
Women 1.4 0.4 1 96
Men 1 1.1 0.1 5912
Major bleeding
Women 2.8 2.6 0.2 541
Men 2.6 2.6 0.04 2474
Minor bleeding
Women 2.6 1.8 0.8 911
Men 2.6 2.9 0.3 268
CVM indicates cardiovascular mortality; MACE, major cardiovascular event; MI,
myocardial infarction; NNH, number needed to harm; NNT, number needed to treat;
NSTEMI, non–ST-segment–elevation myocardial infarction; ST, stent thrombosis.
*DISPERSE-2 (Dose Conﬁrmation Study Assessing Anti-Platelet Effects of AZD6140 vs
Clopidogrel in NSTEMI 2), TRILOGY ACS (Targeted Platelet Inhibition to Clarify the
Optimal Strategy to Medically Manage Acute Coronary Syndromes), and PLATO (Platelet
Inhibition and Patient Outcomes) trials deﬁned stroke as either ischemic or hemorrhagic.
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long-term treatment, but a lower risk of bleeding with no
sex differences was observed.
High potent P2Y12 inhibitors prasugrel, ticagrelor, and
cangrelor have a stronger antiplatelet action and therefore
are also effective in patients with HPR. Two sex-speciﬁc meta-
analyses assessing the efﬁcacy and safety of high-potent DAPT
were previously published. Lau et al34 included 7 trials involving
87 840 patients (24 494 women) with CAD and found no sex
differences for MACE or major bleeding. However, in this meta-
analysis, 3 trials assessing cangrelor were included and the
effect of cangrelor, prasugrel, and ticagrelor was pooled, while
we excluded trials assessing cangrelor in our meta-analysis
because this drug is intravenously administered and only
prescribed in the ﬁrst 48 hours following PCI.
A less extensive meta-analysis compared with the current
study was published by Zaccardi et al,35 consisting of 3 trials
with 24 844 patients (7232 women) testing prasugrel versus
clopidogrel or placebo and 1 trial with 18 624 participants
(5288 women) treated with ticagrelor versus clopidogrel.
No signiﬁcant differences were found in cardiovascular or
bleeding events in the prasugrel or ticagrelor subgroups.35
Therefore, our results are in line with these meta-analyses but
add to the current literature in that it contains the largest number
of studies and patients treated with high potent DAPT according
to the recommendations of the current guidelines in patients who
are treated >1 year. With this meta-analysis we show that the
guidelines statement that no relevant sex differences in efﬁcacy
and safety of DAPT exist, can be validated.
Management of Men and Women With ACS
Women have worse cardiovascular outcomes than men after
ACS.36,37 Underlying causes for this are women’s higher age
at ACS and women having more comorbidities than men, such
as diabetes mellitus, hypertension, and renal failure.36
Moreover, differences in the management of ACS in women
have been suggested as a reason for worse clinical outcomes.
Multiple registry studies have shown that women with ACS
are less likely to be treated according to the guidelines.8,37–39
The SWEDEHEART (Swedish Web-System for Enhancement
and Development of Evidence-Based Care in Heart Disease
Evaluated According to Recommended Therapies) registry
previously showed that women with ST-segment–elevation
myocardial infarction (STEMI) are less likely to be given
reperfusion therapy.40
Figure 4. The relative risk (RR) of major bleeding in women treated with a high potent P2Y12 inhibitor
(prasugrel/ticagrelor) vs clopidogrel. ACS indicates acute coronary syndrome; DISPERSE-2, Dose
Conﬁrmation Study Assessing Anti-Platelet Effects of AZD6140 vs Clopidogrel in NSTEMI 2; NSTEMI, non–
ST-segment–elevation myocardial infarction; PCI, percutaneous coronary intervention; PLATO, Platelet
Inhibition and Patient Outcomes; PRASFIT-ACS, Prasugrel Compared With Clopidogrel for Japanese Patients
With ACS Undergoing PCI; TRILOGY ACS, Targeted Platelet Inhibition to Clarify the Optimal Strategy to
Medically Manage Acute Coronary Syndromes; TRITON-TIMI 38, Trial to Assess Improvement in Therapeutic
Outcomes by Optimizing Platelet Inhibition with Prasugrel–Thrombolysis in Myocardial Infarction 38.
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Moreover, DAPT is more often prescribed in men than
women with ACS. When DAPT was prescribed in women, the
low-intensity P2Y12 inhibitor clopidogrel was more frequently
used in women compared with men, while the more effective
high potent P2Y12 inhibitor prasugrel was preferred in men.
41
The most likely reason for this undertreatment is the
hypothetical concern for higher risk of bleeding in
women.42,43 Regarding milder forms of bleeding, it should
be noted that access site hematomas occur more often in
women than men (22% versus 5.8%, respectively;
P<0.0001).44 However, we showed no evidence for an
increased risk of major bleeding in women. Therefore, more
research on bleeding avoidance strategies is warranted to
reduce access site hematomas, especially in women, but it is
unjustiﬁed to treat women differently or less aggressively with
DAPT in the long term because of risk for major bleeding.
Moreover, in the 2 years following PCI, both physician-
recommended disruption (mostly because of bleeding) and
nonrecommended disruption of DAPT (because of patient
noncompliance) were more common in women than in men
(59.1% versus 55.9%, respectively; P=0.007).41,45 The impact
of DAPT cessation was similar in women and men, with
disruption signiﬁcantly associated with ischemic and bleeding
events in both sexes.45,46 Therefore, it is important to resume
DAPT after cessation to prevent cardiovascular events in the
long term in both sexes.
Study Strengths and Limitations
Our meta-analysis included all contemporary studies using
guideline-recommended high potency DAPT. Treatment in control
groups was homogeneous (clopidogrel+aspirin), and we reported
an average follow-up of at least 1 year, thus describing the
longer-term effects of high potency DAPT in women and men.
Limitations are that we found inter-trial variations in study
design, study population, follow-up duration, percentage of
women included, dosage of prasugrel/ticagrelor, and deﬁni-
tion of MACE and stroke end points. In addition, it should be
noted that our results are based on RCT data, in which the
included patients may not fully reﬂect real-life patients with
ACS. In particular, women are less likely to be representative
as they develop cardiovascular disease at a later age then
men and might thus exceed the upper age limit determined by
the RCT.47 Also, women with cardiovascular disease in
general have more comorbidities than men, which can lead
to exclusion from an RCT.48 Last, our study added only
Figure 5. The relative risk (RR) of major bleeding in men treated with a high potent P2Y12 inhibitor
(prasugrel/ticagrelor) vs clopidogrel. ACS indicates acute coronary syndrome; DISPERSE-2, Dose
Conﬁrmation Study Assessing Anti-Platelet Effects of AZD6140 vs Clopidogrel in NSTEMI 2; NSTEMI,
non–ST-segment–elevation myocardial infarction; PCI, percutaneous coronary intervention; PLATO, Platelet
Inhibition and Patient Outcomes; PRASFIT-ACS, Prasugrel Compared With Clopidogrel for Japanese Patients
With ACS Undergoing PCI; TRILOGY ACS, Targeted Platelet Inhibition to Clarify the Optimal Strategy to
Medically Manage Acute Coronary Syndromes; TRITON-TIMI 38, Trial to Assess Improvement in Therapeutic
Outcomes by Optimizing Platelet Inhibition with Prasugrel–Thrombolysis in Myocardial Infarction 38.
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received sex-speciﬁc data from 1 extra trial that was not
previously presented; however, the sex-speciﬁc stroke data of
the trials have not been published before in a meta-analysis.34
Conclusions
No signiﬁcant sex differences in efﬁcacy and safety of the
high potent P2Y12 inhibitors were observed and therefore
there is no reason to treat women and men differently. Our
meta-analysis can be used to substantiate the essential
evidence that sex-speciﬁc recommendations regarding the
use of high potent DAPT are unjustiﬁed. Therefore, this
should lead the way to implementation of prescribing
guideline-recommended DAPT in both men and women.
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Table S1. Syntax Electronic Databases 
Provided in the table down below are the syntax used for the different electronic databases. All results were imported into EndNote. After de-duplication the screening process was started. 
Table 1. Database syntax used for the respective electronic databases accessible via Erasmus MC network. 
Embase.com 
('dual antiplatelet therapy'/de OR (((dual OR combin*) NEAR/3 (antiplatelet* OR anti-platelet*)) OR dapt):ab,ti OR (('acetylsalicylic acid'/exp OR 
'acetylsalicylic acid plus clopidogrel'/de OR (acetylsalicyl* OR acetyl-salicyl* OR aspirin):ab,ti) AND ('purinergic p2y receptor antagonist'/exp OR 
(cangrelor OR clopidogrel OR elinogrel OR prasugrel OR regrelor OR ticagrelor OR ticlopidine OR ((P2Y*) NEAR/3 (antagonist* OR 
inhibitor*))):ab,ti))) AND ('coronary artery disease'/exp OR 'ischemic heart disease'/de OR (((myocard* OR coronar*) NEAR/3 (disease* OR infarct* 
OR syndrom* OR acute* OR ischem* OR ischaem* OR obstruct*)) OR angina OR ((heart OR cardiac*) NEAR/3  (infarct* OR ischem* OR 
ischaem*))):ab,ti) AND ('adverse drug reaction'/exp OR 'side effect'/exp OR adverse:lnk OR 'bleeding'/exp OR (adverse* OR side-effect* OR bleeding 
OR hemorrhag* OR haemorrhag* OR (blood NEAR/3 (loss OR effusion))):ab,ti) AND ('Controlled clinical trial'/exp OR 'Crossover procedure'/de OR 
'Double-blind procedure'/de OR 'Single-blind procedure'/de OR (random* OR factorial* OR crossover* OR (cross NEXT/1 over*) OR placebo* OR 
((doubl* OR singl*) NEXT/1 blind*) OR assign* OR allocat* OR volunteer* OR trial OR groups):ab,ti) NOT ([animals]/lim NOT [humans]/lim) NOT 
([Conference Abstract]/lim OR [Letter]/lim OR [Note]/lim OR [Editorial]/lim) AND [english]/lim 
Medline Ovid 
(exp Hydroxymethylglutaryl-CoA Reductase Inhibitors/ OR (statin* OR simvastatin OR rosuvastatin OR pravastatin OR pitavastatin OR lovastatin OR 
atorvastatin OR fluvastatin OR ((hmg OR hydroxymethylglutaryl ) ADJ3 (coa OR coenzyme-A ) ADJ3 inhibitor*)).ab,ti.) AND (exp Coronary Artery 
Disease/ OR exp Myocardial Ischemia/ OR (((myocard* OR coronar*) ADJ3 (disease* OR infarct* OR syndrom* OR acute* OR ischem* OR 
ischaem* OR obstruct*)) OR angina OR ((heart OR cardiac*) ADJ3  (infarct* OR ischem* OR ischaem*))).ab,ti.) AND (Drug-Related Side Effects 
and Adverse Reactions/ OR "adverse effects".fs. OR exp Hemorrhage/ OR (adverse* OR side-effect* OR bleeding OR hemorrhag* OR haemorrhag* 
OR (blood ADJ3 (loss OR effusion))).ab,ti.) AND (Exp Controlled clinical trial/ OR "Double-Blind Method"/ OR "Single-Blind Method"/ OR 
"Random Allocation"/ OR (random* OR factorial* OR crossover* OR cross over* OR placebo* OR ((doubl* OR singl*) ADJ blind*) OR assign* OR 
allocat* OR volunteer* OR trial OR groups).ab,ti.) NOT (Animals/ NOT Humans/) NOT (letter OR news OR comment OR editorial OR congresses 
OR abstracts).pt. AND english.la. 
Cochrane CENTRAL 
((statin* OR simvastatin OR rosuvastatin OR pravastatin OR pitavastatin OR lovastatin OR atorvastatin OR fluvastatin OR ((hmg OR 
hydroxymethylglutaryl ) NEAR/3 (coa OR coenzyme-A ) NEAR/3 inhibitor*)):ab,ti) AND ((((myocard* OR coronar*) NEAR/3 (disease* OR infarct* 
OR syndrom* OR acute* OR ischem* OR ischaem* OR obstruct*)) OR angina OR ((heart OR cardiac*) NEAR/3  (infarct* OR ischem* OR 
ischaem*))):ab,ti) AND ((adverse* OR side-effect* OR bleeding OR hemorrhag* OR haemorrhag* OR (blood NEAR/3 (loss OR effusion))):ab,ti)  
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Table S2. Selection criteria used during title-/abstract- and full-text screening. 
Selection Criteria 
Inclusion Criteria: 
- Subjects with ACS treated with dual antiplatelet therapy (DAPT), which 
includes the use of Aspirin and P2Y12-receptor antagonists 
(prasugrel/ticagrelor) as a form of secondary prevention. 
 
Population: 
- At least 18 years of age 
- Secondary prevention 
- Patients with acute coronary syndrome (STEMI, NSTEMI, myocardial 
infarction, or unstable angina pectoris)  
- Patients were treated for coronary heart disease with revascularization 
either: percutaneous coronary intervention (PCI) + stent placement  
 
Study Type: 
- Double blind, randomized controlled trials, single-blind randomized 
controlled trials, and open-label studies.  
- Original article 
- Published as full text article 
- Written in English language 
- > 50 patients per group 
 
Exclusion Criteria: 
- All other indications not covering ACS 
- Primary prevention studies.  
- Non-human studies (e.g. animal studies) 
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Table S3. Cochrane Collaboration’s Tool 
TRIAL 
SELECTION BIAS 
PERFORMANCE 
BIAS 
DETECTION 
BIAS 
ATTRITION 
BIAS 
REPORTING 
BIAS 
OTHER BIAS RANDOM 
SEQUENCE 
GENERATION 
ALLOCATION 
CONCEALMENT 
DISPERSE -2 1 LOW LOW LOW LOW LOW LOW LOW 
PLATO2 LOW UNCLEAR LOW LOW LOW LOW LOW 
PRASFIT ACS3 LOW UNCLEAR LOW LOW LOW LOW HIGH 
TOPIC4 LOW UNCLEAR LOW LOW LOW LOW LOW 
TRILOGY ACS5 LOW LOW LOW LOW LOW LOW LOW 
TRITON TIMI 386 LOW LOW LOW/UNCLEAR LOW LOW LOW LOW 
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Table S4. Overview of primary efficacy endpoints per included trial. 
TRIAL PRIMARY EFFICACY ENDPOINT 
DISPERSE – 21 Composite of CVM, MI (fatal and non-fatal) and stroke 
PLATO 2 Composite of CVM, MI and stroke 
PRASFIT – ACS3 Incidence of MACE at 24 weeks: composite of:  CVM, non-fatal MI, nonfatal ischemic stroke 
TOPIC4 Composite of: CVM, unplanned hospitalization leading to urgent coronary revascularization, stroke, 
and bleeding episodes as defined by the BARC classification > 2 at 1 year after ACS.  
TRILOGY ACS5 Composite of: CVM, non-fatal MI, and non-fatal stroke.  
TRITON – TIMI 386 Composite of: CVM, non-fatal MI, and non-fatal stroke. 
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Efficacy endpoints: Cardiovascular mortality (CVM), Myocardial infarction (MI), Major adverse cardiovascular events (MACE) 
Table S5. Overview of syntax used in STATATM 
To generate an RR in STATA the following code was 
used:  
gen rr=(mi/ni)/(mc/nc) 
To generate the log RR: gen logrr=log(rr) 
To generate the standard error of the log RR:  gen selogrr=sqrt(1/mi-1/ni+1/mc-1/nc) 
To generate the log lower confidence interval:  gen loglci=logrr-1.96*selogrr 
To generate the log upper confidence interval:  gen loguci=logrr+1.96*selogrr 
To re-calculate the log gen lci=exp(loglci) 
To perform the meta-analysis the metan command was 
used. We performed a fixed effects model, seconded by 
a random effects model. The model was separated by 
gender and sorted per trial included.  
metan mi nmi mc nmc, rr random rfdist label(namevar=trial) xlabel 
(0.5,1,5) xtitle() favours (Favors High Potent DAPT  # Favors 
Control) boxsca(30) 
To calculate the funnel plot the data of each trial were 
pooled into one group and entered into STATA, after 
which the log RR and standard error of the log RR were 
calculated. Using the confunnel command, a contour 
enhanced funnel plot can be plotted.  The Egger’s test 
for small study effects was calculated with the metabias 
command. 
confunnel _ES _selogES 
metabias _ES _selogES, egger 
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Table S6. Overview of excluded articles based on title- and abstract screening.  
ANTICOAGULANT STUDIES 
EXCLUSION BASED ON: ANTIPLATELET THERAPIES OR ANTICOAGULANTS 
THERAPIES SUCH AS CANGRELOR (N=19), ELINOGREL (N = 6), GLYCOPROTEINS 
(N= 74), HEPARIN (N = 258), TICLOPIDINE (N=46), AND THROMBOLYTICS.  
N = 739 
CARDIOVASCULAR DISEASE 
EXCLUSION BASED ON: ATRIAL FIBRILLATION STUDIES (N=82), HEART FAILURE 
(N= 29), HEART VALVE (N=27), PERIPHERAL ARTERIAL DISEASE (N=42), AND 
CORONARY ARTERY BYPASS GRAFT (N=74) 
N = 254 
CEREBROVASCULAR STUDIES 
EXCLUSION BASED ON: CEREBROVASCULAR STUDIES  E.G. STROKE. 
N = 172 
CHILDREN STUDIES 
EXCLUSION BASED ON INCLUSION CRITERIA. 
N = 1 
OTHER MEDICATION 
EXCLUSION BASED ON: CILOSTAZOL (N=50), MONOTHERAPEUTIC STUDIES (N=6), 
PROTONPUMP INHIBITORS (N=72), STATINS (N=77), TRIPLE THERAPY (N=29). 
N = 234 
STUDY DESIGN 
EXCLUSION BASED ON: NO DAPT STUDIES (N=323), NO RCT (N=1229), PRIMARY 
PREVENTION (N=7), STUDY DESIGN (N=26), SYSTEMTIC REVIEWS (N=117), TITLE 
AND ABSTRACT (N=169), DOUBLES (N=6), FOLLOW-UP STUDIES (N=2), NO 
ABSTRACT (N=10), SUBSTUDIES (N=33)  
N = 1922 
PHARMACOLOGY N = 201 
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EXCLUSION BASED ON: PHARAMCODYNAMIC OR PHARMACOKINETIC STUDIES 
(N=131), PLATELET REACTIVITY STUDIES (N=70) 
STENT STUDIES 
EXCLUSION BASED ON: TYPE OF DAPT OR TRIAL FOCUS ON DAPT. 
N = 1026 
 
Due to overflow of the flow-chart excluded articles are noted here separately. Each row is described by a main topic, under which the excluded subtopics (n = ) are described. The right column 
provides the total amount of excluded articles per main-topic. 
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 Figure S1. The relative risk of all-cause mortality in women treated with a high potent P2Y12 inhibitor (prasugrel/ticagrelor) vs. clopidogrel. 
 
 
NOTE: Weights are from random effects analysis
.       (0.75, 1.11)with estimated predictive interval
Overall  (I-squared = 0.0%, p = 0.838)
ID
PLATO
Study
DISPERSE
TRILOGY ACS
TOPIC prasugrel
TOPIC ticagrelor
TRITON TIMI 38
PRASFIT-ACS
0.91 (0.79, 1.05)
RR (95% CI)
0.84 (0.68, 1.05)
1.69 (0.32, 9.06)
0.98 (0.79, 1.21)
(Excluded)
0.70 (0.05, 10.58)
0.87 (0.61, 1.24)
1.57 (0.38, 6.43)
100.00
Weight
40.81
%
0.68
42.27
0.00
0.26
15.02
0.96
Favors high potent P2Y12i  Favors Control 
1.5 5
ACM - Women
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 Figure S2. The relative risk of all-cause mortality in men treated with a high potent P2Y12 inhibitor (prasugrel/ticagrelor) vs. clopidogrel 
NOTE: Weights are from random effects analysis
.       (0.75, 0.98)with estimated predictive interval
Overall  (I-squared = 0.0%, p = 0.469)
TRILOGY ACS
ID
PRASFIT-ACS
TRITON TIMI 38
TOPIC prasugrel
TOPIC ticagrelor
PLATO
DISPERSE
Study
0.86 (0.77, 0.95)
0.92 (0.77, 1.09)
RR (95% CI)
0.80 (0.22, 2.97)
1.00 (0.79, 1.26)
0.53 (0.05, 5.74)
0.34 (0.01, 8.32)
0.76 (0.64, 0.89)
1.60 (0.27, 9.45)
100.00
36.88
Weight
0.63
19.20
0.19
0.11
42.66
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%
Favors high potent P2Y12i  Favors Control 
1.5 5
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Figure S3. The relative risk of cardiovascular mortality in women treated with a high potent P2Y12 inhibitor (prasugrel/ticagrelor) vs. clopidogrel 
NOTE: Weights are from random effects analysis
.       (0.71, 1.09)with estimated predictive interval
Overall  (I-squared = 0.0%, p = 0.764)
PRASFIT ACS
ID
TOPIC prasugrel
PLATO
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Study
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0.88 (0.76, 1.03)
2.35 (0.46, 11.91)
RR (95% CI)
(Excluded)
0.82 (0.65, 1.03)
0.91 (0.61, 1.37)
0.92 (0.72, 1.17)
0.70 (0.05, 10.58)
1.69 (0.32, 9.06)
100.00
0.89
Weight
0.00
44.07
14.14
39.75
%
0.32
0.83
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1.5 5
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 Figure S4. The relative risk of cardiovascular mortality in men treated with a high potent P2Y12 inhibitor (prasugrel/ticagrelor) vs. clopidogrel 
 
NOTE: Weights are from random effects analysis
.       (0.73, 0.99)with estimated predictive interval
Overall  (I-squared = 0.0%, p = 0.770)
TRILOGY ACS
PLATO
Study
ID
DISPERSE
PRASFIT ACS
TOPIC ticagrelor
TRITON TIMI 38
TOPIC prasugrel
0.85 (0.76, 0.96)
0.94 (0.78, 1.14)
0.78 (0.66, 0.93)
RR (95% CI)
1.06 (0.15, 7.48)
1.00 (0.25, 3.99)
0.34 (0.01, 8.32)
0.88 (0.66, 1.16)
0.21 (0.01, 4.35)
100.00
36.33
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%
Weight
0.35
0.69
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 Figure S5. The relative risk of myocardial infarction in women treated with a high potent P2Y12 inhibitor (prasugrel/ticagrelor) vs. clopidogrel 
 
NOTE: Weights are from random effects analysis
.       (0.75, 1.04)with estimated predictive interval
Overall  (I-squared = 0.0%, p = 0.987)
TRITON TIMI 38
ID
PLATO
Study
TOPIC prasugrel
TRILOGY ACS
TOPIC ticagrelor
PRASFIT-ACS
DISPERSE
0.88 (0.78, 1.00)
0.88 (0.71, 1.10)
RR (95% CI)
0.83 (0.67, 1.02)
0.75 (0.18, 3.06)
0.95 (0.76, 1.19)
1.05 (0.19, 5.77)
0.94 (0.49, 1.81)
0.85 (0.17, 4.11)
100.00
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Weight
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%
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1.5 5
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 Figure S6. The relative risk of myocardial infarction in men treated with a high potent P2Y12 inhibitor (prasugrel/ticagrelor) vs. clopidogrel 
NOTE: Weights are from random effects analysis
.       (0.64, 1.06)with estimated predictive interval
Overall  (I-squared = 29.2%, p = 0.205)
TRITON TIMI 38
DISPERSE
ID
TRILOGY ACS
TOPIC ticagrelor
TOPIC prasugrel
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PRASFIT-ACS
Study
0.82 (0.74, 0.93)
0.73 (0.64, 0.83)
0.80 (0.34, 1.85)
RR (95% CI)
0.96 (0.81, 1.15)
1.21 (0.57, 2.59)
0.73 (0.32, 1.66)
0.85 (0.74, 0.98)
0.69 (0.46, 1.04)
100.00
32.12
1.80
Weight
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%
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1.5 5
MI - Men
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 Figure S7. The relative risk of stent thrombosis in women treated with a high potent P2Y12 inhibitor (prasugrel/ticagrelor) vs. clopidogrel 
TOPIC ticagrelor and PRASFIT ACS were excluded because there were no events during follow-up. DISPERSE-2 was excluded because there was no stent thrombosis endpoint 
reported. 
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 Figure S8. The relative risk of stent thrombosis in men treated with a high potent P2Y12 inhibitor (prasugrel/ticagrelor) vs. clopidogrel 
TOPIC prasugrel was excluded because there were no events during follow-up. DISPERSE-2 was excluded because there was no stent thrombosis endpoint reported. 
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 Figure S9. The relative risk of stroke in women treated with a high potent P2Y12 inhibitor (prasugrel/ticagrelor) vs. clopidogrel 
TOPIC ticagrelor was excluded because there were no events during follow-up. 
DISPERSE-2, TRILOGY ACS and PLATO defined stroke as either ischemic or hemorrhagic.  
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 Figure S10. The relative risk of stroke in men treated with a high potent P2Y12 inhibitor (prasugrel/ticagrelor) vs. clopidogrel 
TOPIC ticagrelor was excluded because there were no events during follow-up. 
DISPERSE-2, TRILOGY ACS and PLATO defined stroke as either ischemic or hemorrhagic.  
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 Figure S11. The relative risk of minor bleeding in women treated with a high potent P2Y12 inhibitor (prasugrel/ticagrelor) vs. clopidogrel 
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 Figure S12. The relative risk of minor bleeding in men treated with a high potent P2Y12 inhibitor (prasugrel/ticagrelor) vs. clopidogrel 
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 Test of H0: no small-study effects          P = 0.270 
Figure S13. Contour enhanced funnel plot of MACE in women 
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 Test of H0: no small-study effects          P = 0.826 
Figure S14. Contour enhanced funnel plot of MACE in men 
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 Test of H0: no small-study effects          P = 0.271 
Figure S15. Contour enhanced funnel plot of ACM in women 
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 Test of H0: no small-study effects          P = 0.779 
Figure S16. Contour enhanced funnel plot of ACM in men 
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 Test of H0: no small-study effects          P = 0.125 
Figure S17. Contour enhanced funnel plot of CVM in women 
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 Test of H0: no small-study effects          P = 0.878 
Figure S18. Contour enhanced funnel plot of CVM in men 
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 Test of H0: no small-study effects          P = 0.864 
Figure S19. Contour enhanced funnel plot of MI in women 
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 Test of H0: no small-study effects          P = 0.747 
Figure S20. Contour enhanced funnel plot of MI in men 
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Test of H0: no small-study effects          P = 0.648 
Figure S21. Contour enhanced funnel plot of ST in women 
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 Test of H0: no small-study effects          P = 0.352 
Figure S22. Contour enhanced funnel plot of ST in men  
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 Test of H0: no small-study effects          P = 0.952 
 
Figure S23. Contour enhanced funnel plot of stroke in women 
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Test of H0: no small-study effects          P = 0.416 
Figure S24. Contour enhanced funnel plot of stroke in women 
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 Test of H0: no small-study effects          P = 0.366 
Figure S25. Contour enhanced funnel plot of major bleeding in women  
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 Test of H0: no small-study effects          P = 0.745 
Figure S26. Contour enhanced funnel plot of major bleeding in men  
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 Test of H0: no small-study effects          P = 0.632 
Figure S27. Contour enhanced funnel plot of minor bleeding in women  
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 Test of H0: no small-study effects          P = 0.829 
Figure S28. Contour enhanced funnel plot of minor bleeding in men  
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